Drug Trial Radar · NCT06685757
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
132
Actual
Start
Dec 3, 2024
Primary completion
Dec 1, 2026
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure. But even after a successful transplant, the body's immune system can sometimes attack the new kidney. Antibody-mediated rejection (AMR) is when a person's immune system attacks a transplanted organ, like a new kidney. In the person receiving the transplant, their immune system creates specific antibodies. Antibodies are proteins that help the body fight infections. In people with AMR, these antibodies mistakenly see the new organ as a threat and damage its blood vessels. This can cause the new organ to fail. In this study, researchers will learn more about how a study drug called felzartamab affects people with AMR. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce antibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works in participants with kidney transplants who experience AMR compared to a placebo. A placebo is something that looks like the study drug but does not contain any medicine. A placebo is also given in the same way as the study drug. All participants in this study will have active AMR or AMR that has lasted for at least 6 months after their kidney transplant. The main question that researchers want to answer is: • How many participants have biopsy results showing that their transplanted kidney tissue looks normal or near normal after 24 weeks of treatment? Researchers will also learn about: * How long it takes before the participants' disease gets worse * How long the participants' urine protein levels stay low * Kidney biopsy scores to check for blood vessel inflammation at 6 months and 1 year * How many people have no blood vessel inflammation at these times * Changes in donor deoxyribonucleic acid (DNA) levels in blood from the start of treatment * Biopsy test scores for signs of rejection and inflammation at 6 months and 1 year * Changes in kidney function from the start of treatment * How many people have biopsy results showing their kidney tissue looks normal again * How long the transplanted kidney keeps working * How many participants have medical problems during the study * How many participants show signs of another type of kidney transplant rejection called T-cell-mediated rejection (TCMR) at Week 24 and Week 52 * How do results from vital signs, electrocardiograms (ECGs), and blood and urine tests change over time * How felzartamab is processed by the body * How many participants develop antibodies against felzartamab in the blood The study will be done as follows: * Participants will be screened to check if they can join the study. This will take up to 42 days. * There will be 2 parts in this study. * Part A of the study is "double blind." This means that neither the participants, study doctor, or site staff know if the participants received the study drug or a placebo. During Part A, participants will be randomized to receive up to 9 doses of either felzartamab or placebo. * Part B of the study is "open label." This means that the participants, study doctor, and site staff know which study drug the participant is receiving. During Part B, all participants from Part A will receive up to 9 doses of felzartamab. * All doses will be given through an "intravenous" infusion. This means it will be given into a vein. The dose the participants receive will depend on their body weight. * Part A will last up to 24 weeks. Part B will last up to 28 weeks. In total, participants will have up to 21 study visits and will be in the study for about 1 year.
Conditions
- Antibody-mediated Rejection
Interventions
FelzartamabDrug
Participants will receive felzartamab by intravenous infusion.
PlaceboDrug
Participants will receive 0.9% saline solution by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants Who Achieve Biopsy-proven Histologic Resolution (BPHR)Time frame: Week 24
Locations
56 sites in 12 countries. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
UCLA
Los Angeles, California
Providence Healthcare
Orange, California
Loma Linda
San Bernardino, California
California Pacific Medical Center
San Francisco, California
University of California, San Francisco
San Francisco, California
University of Colorado
Aurora, Colorado
University of Chicago
Chicago, Illinois
University of Kansas
Kansas City, Kansas
Tulane University Health Sciences Center
New Orleans, Louisiana
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
University of Nebraska
Omaha, Nebraska
Cooperman Barnabas Medical Center
West Orange, New Jersey
Duke University
Durham, North Carolina
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Penn Medicine - Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University
Nashville, Tennessee
UT Southwestern Medical Center
Dallas, Texas
Houston Methodist
Houston, Texas
Virginia Commonwealth University
Richmond, Virginia
University of Washington Medical Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Clinica Privada Velez Sarsfield
Córdoba, Argentina
Instituto de Trasplante y Alta Complejidad (ITAC)
Cdad, Autónoma de Buenos Aires, Argentina
Princess Alexandra Hospital
Woolloongabba, Australia
Royal Melbourne Hospital
Parkville VIC, Australia, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Medical University of Vienna
Spitalgasse, State of Vienna, Austria
Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vicente Scherer
Centro Histórico, Porto Alegre - RS, Brazil
Hospital de Base da Faculdade de Medicina de São José do Rio Preto
Vila São José, São José Do Rio Preto, Brazil
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Cerqueira César, São Paulo, Brazil
Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
Vila Clementino, São Paulo, Brazil
University of Alberta
Edmonton, Alberta, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
The University of British Columbia (UBC)/St. Paul's Hospital part of Providence Health Care
Vancouver, British Columbia, Canada
McGill University
Montreal, Quebec, Canada
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.